Table 1.

Patient characteristics

Characteristic		High-dose group (n = 55)	Low-dose group(n = 58)	All cases (n = 113)
Age (years)	Median	67	62.5	65
	Range	49–83	36–83	36–83
Gender	Male	24	21	45
	Female	31	37	68
Performance status	0	35	33	68
	1	18	24	42
	2	2	1	3
Primary site	Colorectum	20	8	28
	Uterine cervix	9	18	27
	Endometrium	5	10	15
	Ovary	8	2	10
	Urothelial	4	4	8
	Others	9	16	25
Histopathology	Adenocarcinoma	41	31	72
	Squamous cell carcinoma	10	23	33
	Others	4	4	8
Initial category	T-category 1:2:3:4	13:20:18:4	18:13:19:8	31:33:37:12
	N-category positive	32	32	64
Duration from initial diagnosis (months)	Median	25.4	22.4	24.1
	Range	2.9–102.4	1.9–100.4	1.9–102.4
DFI (months)	Median	8.7	8.3	8.5
	Range	0.6–64.4	0.5–86.6	0.5–86.6
Radiation therapy method	3DCRT	12	35	47
	SBRT&IMRT	43	23	66
LN site	Para-aortic	29	43	72
	Iliac	8	10	18
	Presacral	9	3	12
	Obturator	9	2	11
Extra-regional LN for primary site	no	37	28	65
	yes	18	30	48
Number of lymph node	1	33	28	61
	2–5	22	30	52
LN size (cm)	Median	2	2	2
	Range	1–5.5	1–5	1–5.5
Prophylactic nodal irradiation	no	40	29	69
	yes	15	29	44
Chemotherapy	no	15	7	22
	yes	40	51	91
Concurrent chemotherapy	no	43	37	80
	yes	12	21	33
EQD2 (Gy)	Median	66.6	50	59.7
	Range	60.4–101.4	40.3–59.8	40.3–101.4
Follow-up time of entire group (months)	Median	20.2	15.9	17.8
	Range	5.8–84.7	3.7–109.8	3.7–109.8
Follow-up time in surviving patients (months)	Median	23	24.2	23.7
	Range	7.6–84.7	4.0–109.8	4.0–109.8

n number of patients, LN lymph node, DFI disease-free interval, 3DCRT 3-dimentional conformal radiation therapy, SBRT Stereotactic Body Radiation Therapy, IMRT intensity-modulated radiation therapy, EQD2 equivalent dose in 2 Gy fraction